Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II high-dose therapy with peripheral blood stem cell support in elderly patients with relapsed or refractory aggressive non-Hodgkin lymphoma
2009-015974-36Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, dexamethasone, cisplatin, cytarabine, etoposide and 1 more in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more, sponsored by Gruppo Italiano Studio Linfomi. Primary endpoints: 1-year event-free survival and Treatment-related mortality. Started Oct 2009; status: completed.
02
Drugs
rituximabdexamethasonecisplatincytarabineetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2009-015974-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015974-36.